
Hanmi Licenses Obesity Candidate HM17321 to Genentech
Hanmi Pharmaceutical granted Genentech exclusive rights outside Korea to develop, manufacture and commercialize the UCN2 analog HM17321 for obesity and related metabolic diseases.
Newsroom
The MediIndex Newsroom produces bilingual health explainers from clearly identified public sources and labels how each article was reviewed.

Hanmi Pharmaceutical granted Genentech exclusive rights outside Korea to develop, manufacture and commercialize the UCN2 analog HM17321 for obesity and related metabolic diseases.

Singer Seo In-young revealed that she underwent upper-arm liposuction while preparing to return to a festival stage after about 10 years.

Actor Jung Ga-eun shared the at-home habits she follows at age 48, including regular massage.

The Korean Dermatological Association advised people with recurring or persistent hand skin problems to seek a dermatologist’s diagnosis instead of judging symptoms or treating them on their own.

The Korean Atopic Dermatitis Association launched its MyTOPI campaign as a patient survey found strong interest in diagnostic testing to help select treatment.

Laseroptek presented its products and discussed business cooperation with local clinicians and industry representatives at Dubai Derma 2026, expanding its contacts in the Middle Eastern medical market.

JungHun Pharmaceutical said its hyaluronic acid filler Lorient was used during the final volume-restoration step of a three-part plan shown on Channel A.

Experts at a September 10 symposium called for appropriate prescribing and effective oversight of GLP-1 obesity drugs as misuse and illegal distribution raised concern.

The Seoul Metropolitan Medical Association said laser device use by Korean medicine doctors should be judged by formal training, licensing scope, and patient safety.

South Korea’s Ministry of Food and Drug Safety is pursuing a designation of GLP-1 obesity drugs as medicines of concern for misuse, targeting completion this month.

South Korea’s drug regulator approved Aju Pharm’s Latika Ophthalmic Solution 5% for improving corneal and conjunctival epithelial disorders in adults with dry eye disease.

Aribio and Aribio Lab received final BPOM marketing authorization in Indonesia for four Bidan hyaluronic acid fillers.